Myriad's MPC-0920 performs well at Ph I
USA-based biopharmaceutcal firm Myriad Genetics has announced the completion of a Phase I trial of MPC-0920, its candidate oral direct thrombin inhibitor. Results from the program, which examined the drug in healthy volunteers in a single escalating dose regimen, showed that it had a "significant biological effect on clotting time and a desirable safety profile."
Myriad said that MPC-0920 is designed to be a rapid-acting anticoagulant and is intended to provide an improved therapeutic window and more predictable response in patients requiring anti-thrombin therapy. The firm went on to say that analysis of the reported data showed that the drug's activity was correlated to observed plasma concentration, and added that no treatment-related events had been observed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze